In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CircuLite: Treating Heart Failure’s Lost Patients

Executive Summary

Even with all of the advances and options in heart failure therapy, there remain no real options for a large number of patients who are seriously ill but not yet at the end-stage of the disease. CircuLite hopes to change that with a partial support device for patients who don’t need a VAD.

You may also be interested in...



Tug Of War In The LVAD Market

With the rivalry between Thoratec and HeartWare intensifying in the LVAD space, all eyes are now on recent strategic acquisitions by both companies, as well as ongoing clinical studies and next-generation devices in the pipeline.

HeartWare Adds Synergy Circulatory Support System With $30 Mil. CircuLite Buy

The acquisition could significantly expand the targeted market base for HeartWare, but first the company will need to re-launch CircuLite’s Synergy in Europe, which experiences a design problem the first time around.

Two Small Companies See Huge Opportunities In Heart Failure Device Space

CardioKinetix, maker of a unique, percutaneously placed ventricular partitioning device, and CircuLite, which is developing a less invasive cardiac assist device, are moving into US clinical trials with their technologies – an important milestone for emerging companies in the difficult heart failure space. Both offer therapies aimed at helping fill the huge heart failure treatment gap that exists today.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel